Press Releases & Statements

Investor Relations

Month Year

Month Year

Complete Trial Results Manuscript of Novavax COVID-19 Investigational Vaccine Posted to Preprint Server medRxiv
- Statement
- COVID-19
May 21, 2021
Novavax Statement on Participation in Mix-and-Match COVID-19 Vaccine Booster Trial in the United Kingdom
- Statement
- COVID-19
May 21, 2021
Novavax Honored by Maryland Tech Council During 2021 Industry Awards Celebration
- Corporate and Finance
May 21, 2021
Novavax Reports First Quarter 2021 Financial Results and Operational Highlights
- Corporate and Finance
May 10, 2021
Novavax Statement on Updated PREVENT-19 Trial Protocol
- Statement
- COVID-19
May 10, 2021
Novavax Announces Positive Preclinical Data for Combination Influenza and COVID-19 Vaccine Candidate
- COVID-19
- Seasonal Influenza
May 10, 2021
Novavax Statement on Ministry of Health, Labour and Welfare’s Announcement Regarding Procurement from Takeda of NVX-CoV2373 for Japan
- Statement
- COVID-19
May 7, 2021
Novavax Statement in Opposition to the WTO TRIPS Waiver
- Statement
- COVID-19
May 7, 2021
Novavax and Gavi Execute Advance Purchase Agreement for COVID-19 Vaccine for COVAX Facility
- COVID-19
May 6, 2021
New England Journal of Medicine Publishes Phase 2b Clinical Trial Results Demonstrating Efficacy of Novavax COVID-19 Vaccine Against the B.1.351 Variant

May 5, 2021

Show per page